The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

##STR00001##

The application relates to a compound having Formula (I): ##STR00001##
which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

The present invention provides a method of reducing uric acid in a subject in need thereof, comprising administering to the subject a composition comprising an effective amount of fucoxanthin, wherein the fucoxanthin has the effect of reducing uric acid and preventing gout.

A xanthine oxidase inhibitor and a uric acid-producing inhibitor, each containing an extract from at least one member selected from the group consisting of Zanthoxylum bungeanum, Sorghum nervosum, Cuminum cyminum, Rosa centifolia, Pimenta officinalis, Origanum majorana, Psidium guajava, Pimpinella anisum, Olea europaea, Illicium verum, Canavalia gladiata, Hyssopus officinalis, Ribes nigrum, Vaccinium myrtillus, Artemisia princeps and Haematoxylon campechianum L.

The present invention relates to methods for treatment of hyperuricemia using GLP-1 receptor agonists. The invention is based on a double-blinded, placebo controlled study in overweight and obese patient where a significant urate lowering was observed in subjects with increased serum urate levels.

The present invention relates to methods for treatment of hyperuricemia using GLP-1 receptor agonists. The invention is based on a double-blinded, placebo controlled study in overweight and obese patient where a significant urate lowering was observed in subjects with increased serum urate levels.

The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

Uses and formulations of cannabinoids, in particular of cannabidiol, are provided.

The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune diseases, chronic inflammatory diseases and inflammatory conditions in connection with infections, including cytokine release syndrome (CRS).

Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from conditions as referred to above.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.